Anti–PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment

BACKGROUND: Numerous preclinical studies have revealed the complex regulatory mechanisms between anti-angiogenesis and immune inhibition in the tumor immune microenvironment and have proposed the efficacy of combined immunotherapy and anti-angiogenic treatment. Moreover, the combination strategy had...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Yonghong, Dong, Ruizeng, Jin, Ting, Jin, Qifeng, Chen, Xiaozhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908371/
https://www.ncbi.nlm.nih.gov/pubmed/35280787
http://dx.doi.org/10.3389/fonc.2022.781348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908371/
https://www.ncbi.nlm.nih.gov/pubmed/35280787
http://dx.doi.org/10.3389/fonc.2022.781348

Ejemplares similares